Join the Center for Molecular Innovation and Drug Discovery (CMIDD) for our annual Colloquium & Scientific Poster Session at Northwestern’s Evanston campus. In partnership with MilliporeSigma, we are bringing together faculty, graduate students, and postdoctoral fellows to exchange their scientific knowledge and showcase the impact of chemistry on medicine.
There will be a Colloquium, followed by a reception and Scientific Poster Session showcasing the research of an elite group of Northwestern graduate students and postdocs. These Scholars were selected based on their innovation and merit within the realm of biomedical research, with demonstrated ability to achieve and contribute to the development of new therapeutics through their current research.
Registration is FREE for this event and closes on AUGUST 24. Please complete the registration form at the bottom of this page.
2:30pm | Abbott Auditorium | Nischita Prasad, Materials Science – North America, MilliporeSigma
“Nanomaterials for Bio-Enabling Future Diagnostics and Treatment”
Abstract: The concept of nanotechnology was defined in 1959, but the benefits of Nanoscience have taken decades to realize. Progress in biomedical applications of nanotechnology have been particularly slow, in large part due to the need for effective conjugation chemistry for the attachment of biomolecules such as peptides, oligonucleotides, antibodies, or proteins to the nanomaterial surface.
Despite of the slow progress, the biomedical applications of nanomaterials have attracted significant attention recently. Nanomaterials play a huge role in the area of future diagnostics and theranostics. Because nanomaterials are the same size as proteins and other cellular components (≤100 nm), they can interact with living cells and their constituents in unique ways and thus, biomolecule-nanomaterial conjugates have the potential for many applications, including early and rapid disease detection. In this seminar, we will focus on bioconjugation of the nanoparticles, associated challenges and common nanomaterials being investigated in diagnostics/theranostics related research.
3:15pm | Abbott Auditorium | Joseph Moskal, PhD, Director of the Falk Center for Molecular Therapeutics; Professor of Biomedical Engineering; Professor of Neurological Surgery (MED), Northwestern University
“The Development of Rapastinel (Formerly GLYX-13); A rapid acting and long-lasting antidepressant and the evolution of a novel molecular platform for elucidating the role of N-methyl-D-aspartate (NMDA) receptors in synaptic plasticity”
Abstract: N-methyl-D-aspartate (NMDA) receptors are one of a family of ligand gated ionotropic glutamate receptors that are found predominantly in the central nervous system (CNS) and developmentally regulated. They play a pivotal role in modulating normal neuronal functions including synaptic plasticity associated with learning and memory. NMDA receptors have also been implicated in a variety of CNS disorders including schizophrenia, mood disorders, epilepsy, neuropathic pain, Rett syndrome, and cognitive decline due to normal aging among others.
Rapastinel (GLYX-13) is a unique NMDA receptor modulator with robust cognitive enhancing properties that also shows rapid and long-lasting antidepressant properties in both animal models and in humans. Rapastinel was derived from a monoclonal antibody, B6B21, is a tetrapeptide (threonine-proline-proline-threonine-amide) obtained from amino acid sequence information obtained from sequencing one of the hypervariable regions of the light chain of B6B21. Mechanistically, GLYX-13 appears to bind directly to NMDA receptors triggering an increase in AMPA receptor activity leading to a long-term potentiation-like increase in synaptic plasticity associated with learning.
A key structural feature of GLYX-13 is its dipyrrolidine-based beta-turn motif. In order to exploit this in an attempt to design and synthesize a novel family of compounds with GLYX-like therapeutic properties but, unlike GLYX-13, with oral bioavailability, a novel chemical platform was created using spiro-beta-lactam (SBL) chemistry. A representative compound from this platform, NYX-2925, is an excellent GLYX-13 mimetic with potentially better therapeutic potential than GLYX-13 due to its large therapeutic index, functional properties and oral bioavailability. Moreover, NYX-2925 and two other molecules from this platform have been approved for clinical trials for neuropathic pain, fibromyalgia and PTSD.
4:00pm – 5:00pm | 2nd Floor Cafe | Reception & Scientific Poster Session
Join us for CMIDD’s annual scientific poster session showcasing research being conducted by graduate students and postdocs in the area of chemistry at the interface with biology and medicine. Recipients of the Best Poster Awards will be announced. The session also allows the opportunity to meet representatives from our event sponsor, MilliporeSigma.
Refreshments will be provided.
Registration is FREE for this event. Please complete the registration form below by Friday, August 24, 2018.